SCHEMBL3237674

SCHEMBL3237674

O=C(c1ccc(NCc2ccc(Cl)c(Cl)c2)cc1)N1CCCCC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.59
ALDH1A1 P00352 4/20 0.59
MAPT P10636 4/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
FFAR1 O14842 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
IKBKB O14920 1/20 0.49
HSD11B1 P28845 2/20 0.49
PKM P14618 1/20 0.49
NAMPT P43490 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3242897 0.89 MAPT (0.54) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL3259882 0.86 ALDH1A1 (0.70) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL3237671 0.85 HPGD (0.59) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL3241843 0.84 NPC1 (0.63) HPGDALDH1A1MAPTL3MBTL1NPC1
SCHEMBL3268298 0.84 HPGD (0.44) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL912044 0.81 MEN1 (0.50) ALDH1A1MAPTMEN1KMT2AFFAR1
SCHEMBL1711101 0.80 SLC6A7 (0.67) HPGDALDH1A1MAPTL3MBTL1NPC1
SCHEMBL11248617 0.78 FFAR1 (0.69) ALDH1A1MAPTMEN1KMT2AFFAR1
SCHEMBL6280995 0.78 HPGD (0.96) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL3242896 0.75 MAPT (0.54) HPGDALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 HPGD 3739/4885ALDH1A1 1588/4885MAPT 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.